# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
A sponsored exhibitor session will feature Dr. Phillip Michaels from Harvard Medical School and Brigham and Women's Hospita...
Bionano Genomics, Inc. (NASDAQ:BNGO), today announced the publication of the first multi-site study in multiple myeloma (MM) co...
A sponsored session will feature Dr. Lucia Gallego Villarejo from Ruhr University Bochum, Dr. Jeanne Loring from Scripps Resear...
Bionano Laboratories, a clinical laboratory services business of Bionano Genomics, Inc. (NASDAQ:BNGO), today announced the edit...
Bionano Genomics Inc. ("Bionano" or the "Company") (NASDAQ:BNGO) today announced that it has completed a privat...
Three peer-reviewed publications collectively illustrate the building support for optical genome mapping (OGM) as a tool for ce...
BTIG analyst Mark Massaro maintains Bionano Genomics (NASDAQ:BNGO) with a Buy and lowers the price target from $3 to $2.